DexCom, Inc. (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Steven Robert Pacelli also recently made the following trade(s):

  • On Monday, July 24th, Steven Robert Pacelli sold 1,450 shares of DexCom stock. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50.

DexCom, Inc. (NASDAQ DXCM) opened at 48.925 on Friday. The company’s market cap is $4.23 billion. DexCom, Inc. has a 52-week low of $45.61 and a 52-week high of $94.24. The company’s 50-day moving average is $72.62 and its 200 day moving average is $73.86.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. During the same quarter in the prior year, the firm earned ($0.24) EPS. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. Equities analysts forecast that DexCom, Inc. will post ($0.79) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/30/insider-selling-dexcom-inc-dxcm-evp-sells-101224-50-in-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Janus Henderson Group PLC increased its position in shares of DexCom by 101,699.8% during the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock valued at $499,522,000 after purchasing an additional 6,822,023 shares during the last quarter. BlackRock Inc. increased its position in shares of DexCom by 5,000.4% during the 1st quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock valued at $352,550,000 after purchasing an additional 4,079,283 shares during the last quarter. Winslow Capital Management LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at about $117,451,000. FMR LLC increased its position in shares of DexCom by 9.9% during the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of DexCom by 27.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock valued at $237,221,000 after purchasing an additional 696,199 shares during the last quarter.

Several research analysts have weighed in on the stock. Wedbush restated an “outperform” rating and set a $76.00 price objective (down previously from $85.00) on shares of DexCom in a report on Thursday. Raymond James Financial, Inc. downgraded shares of DexCom from an “outperform” rating to a “mkt perform” rating in a report on Friday. Leerink Swann restated a “buy” rating and set a $57.00 price objective on shares of DexCom in a report on Friday. Piper Jaffray Companies restated a “buy” rating and set a $78.00 price objective on shares of DexCom in a report on Wednesday, July 12th. Finally, J P Morgan Chase & Co downgraded shares of DexCom from an “overweight” rating to a “neutral” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and a consensus price target of $75.38.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.